WAT

Business Profile & Competitive Position

Waters Corporation sits in the Healthcare sector under the Medical - Diagnostics & Research industry. It designs, manufactures, sells and services analytical instruments, led by high-performance and ultra-performance liquid chromatography (LC), mass spectrometry (MS), thermal analysis, rheometry and calorimetry (TA) instruments. Those product lines are typically bundled with consumables, software and service plans, and are sold as integrated LC-MS systems running common software.

Following the February 2026 acquisition of BD’s Biosciences and Diagnostic Solutions businesses, Waters also offers diagnostics specimen collection, infectious-disease/cancer testing systems, flow cytometry and multiomics tools. End markets include pharmaceutical, clinical, biochemical, industrial, nutritional-safety, environmental, academic and government laboratories.

The current margin profile—net margin of 3.6% and ROE of 1.9%—is modest for an analytical-instrument franchise, and it suggests the business is not currently generating the kind of returns typically associated with a deep competitive moat. In 2025, service revenue represented more than 35% of Waters’ sales and more than 25% of TA’s sales, which supports a recurring-revenue element, but that has not translated into strong bottom-line returns. Customer concentration is low: no single customer accounted for more than 2% of 2025 net sales, and the mix was 59% pharmaceutical, 30% other industrial and 11% academic/government. The low margins and ROE are most plausibly read as the immediate byproduct of acquisition-related integration, restructuring and accounting effects from the $16.8 billion BD transaction, rather than evidence of a durable moat at this moment.

Financial Posture

Waters currently carries a market capitalization of $30.5 billion and trades at a P/E of 101.4. Set against a 3.6% net margin and 1.9% ROE, that multiple is extremely elevated relative to current earnings power. A beta of 1.18 means the stock has historically moved somewhat more than the overall market, implying higher volatility.

At the snapshot price of $407.77, RSI was 62.5 and the 50-day EMA was $379.46, so the stock was trading above its intermediate-term moving average. The valuation, however, looks reliant on a multi-year turnaround narrative: successful integration of the BD businesses, cost synergies, revenue uplift from diagnostics and eventual margin expansion. Whether that narrative materializes is an execution question that the current profitability figures alone cannot answer.

Strategic Priorities & Outlook

Waters’ most recent 10-K describes a company in the middle of a structural overhaul. Management’s immediate priorities are to reorganize the combined company into four segments—Waters Analytical Sciences, Waters Biosciences, Waters Advanced Diagnostics and Waters Materials Sciences—and then evaluate the newly organized activities for future operating and reporting segments. The company also intends to continue significant R&D investment to develop new products and enhance existing LC, MS, TA and diagnostics offerings, while pursuing additional outsourcing opportunities as they arise and maintaining adequate internal supply chain and manufacturing capabilities.

The BD Biosciences and Diagnostic Solutions acquisition closed on February 9, 2026, for a total purchase price of $16.8 billion including assumed debt. It was structured as a Reverse Morris Trust, with BD shareholders owning approximately 39.2% of the combined company. That is a transformative transaction, and the 10-K makes clear that segment reporting, integration costs and product-line rationalization will dominate the operating narrative for several quarters.

Macro & Geopolitical Exposure

As a Healthcare / Medical - Diagnostics & Research company, Waters faces macro exposures common to regulated life-science toolmakers. Its instruments and diagnostics are subject to oversight by the FDA and comparable foreign health authorities, covering quality systems, clinical validation for diagnostics and post-market surveillance. Changes in reimbursement policy, diagnostic testing guidelines or pharmaceutical R&D spending can materially shift demand.

Trade policy is also relevant: LC, MS and TA platforms contain precision components sourced globally, so tariffs or export controls can raise costs or limit market access. International revenue creates currency exposure, and specialized detectors, chips, gases and chemicals create supply-chain dependencies. Finally, government and academic spending patterns influence the 11% of 2025 sales tied to those customers.

Recent Developments

Recent news flow has been light but includes several concrete data points:

• On August 15, 2026, defenseworld.net reported that Assetmark Inc. holds a $1.57 million stake in Waters Corporation.
• On August 10, 2026, defenseworld.net reported that Dudley & Shanley Inc. holds an $8.85 million stake.
• On the same day, defenseworld.net noted that a Waters Director sold $1,442,930.44 in stock.
• On August 9, 2026, marketbeat.com published “Waters Q2 Earnings Call Highlights.”

The insider sale is a factual event rather than a directional signal, but it stood out because it occurred only days after the August 4, 2026 earnings report. The reported institutional stakes are modest in headline dollar terms compared with the $30.5 billion market cap, so larger position changes by major asset managers could still drive meaningful price action.

Earnings Behavior & Post-Earnings Drift

Waters has an impeccable earnings record over the last eight reported quarters: 8 out of 8 beats, with an average earnings surprise of 4.7%. The average five-day post-earnings price move has been 2.67% to the upside, classified as an “up” drift.

The most recent four quarters show how that average is built:

• August 4, 2026: EPS of $3.05 versus the estimate of $3.01, a 1.3% surprise. The stock rose 0.99% the next session and 4.78% over the following five days.
• May 5, 2026: EPS of $2.70 versus $2.31, a 16.9% surprise. The stock gained 2.04% the next day and 2.83% over the next five days.
• February 9, 2026: EPS of $4.53 versus $4.51, a 0.4% surprise. The stock slipped 0.34% the next day and fell 2.04% over the following five days, breaking the positive streak around the BD deal close.
• November 4, 2025: EPS of $3.40 versus $3.21, a 5.9% surprise. The stock rose 1.26% the next day and 5.12% over the subsequent five days.

Next on the calendar is the November 3, 2026 before-open report, with a consensus EPS estimate of $4.01. The current price near $407.77 means the market is carrying a substantial expectations bar, and while post-earnings drift has historically been positive, it has not been uniform. The February 2026 quarter is a useful reminder that even an EPS beat can be met with short-term selling when the surprise is small and integration noise is high.

For a deeper dive into how sell-side and institutional models are interpreting the BD integration, margin recovery path and post-earnings setup, see the full institutional verdict on Waters Corporation.